Anixa Biosciences’ (ANIX) Buy Rating Reiterated at HC Wainwright

Anixa Biosciences (NASDAQ:ANIX)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $7.00 target price on the stock. HC Wainwright’s price target would indicate a potential upside of 118.75% from the company’s current price.

A number of other research analysts have also issued reports on ANIX. D. Boral Capital reissued a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a research note on Wednesday, January 22nd. Maxim Group started coverage on Anixa Biosciences in a research report on Friday. They set a “buy” rating and a $10.00 price objective for the company.

Anixa Biosciences Trading Up 1.3 %

Shares of Anixa Biosciences stock opened at $3.20 on Tuesday. Anixa Biosciences has a twelve month low of $2.07 and a twelve month high of $4.20. The stock has a market capitalization of $103.03 million, a price-to-earnings ratio of -8.21 and a beta of 0.86. The business’s 50 day simple moving average is $2.91 and its 200-day simple moving average is $3.00.

Anixa Biosciences (NASDAQ:ANIX) last posted its earnings results on Tuesday, March 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). Sell-side analysts predict that Anixa Biosciences will post -0.41 earnings per share for the current year.

Insider Activity at Anixa Biosciences

In other Anixa Biosciences news, Director Lewis H. Titterton, Jr. purchased 10,000 shares of the company’s stock in a transaction on Friday, January 17th. The shares were purchased at an average cost of $2.57 per share, for a total transaction of $25,700.00. Following the completion of the transaction, the director now owns 922,334 shares in the company, valued at $2,370,398.38. The trade was a 1.10 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Amit Kumar acquired 43,000 shares of Anixa Biosciences stock in a transaction dated Wednesday, January 15th. The shares were acquired at an average price of $2.23 per share, with a total value of $95,890.00. Following the transaction, the chief executive officer now owns 559,925 shares in the company, valued at approximately $1,248,632.75. This represents a 8.32 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased 75,289 shares of company stock worth $177,021 in the last 90 days. Corporate insiders own 25.30% of the company’s stock.

Institutional Trading of Anixa Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Focus Partners Wealth acquired a new position in Anixa Biosciences in the fourth quarter worth approximately $162,000. LPL Financial LLC lifted its position in shares of Anixa Biosciences by 37.2% during the 4th quarter. LPL Financial LLC now owns 42,937 shares of the company’s stock valued at $100,000 after acquiring an additional 11,633 shares during the last quarter. Westside Investment Management Inc. boosted its stake in shares of Anixa Biosciences by 151.8% during the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after acquiring an additional 21,100 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Anixa Biosciences in the 4th quarter worth $67,000. Finally, Prosperity Wealth Management Inc. acquired a new stake in shares of Anixa Biosciences during the fourth quarter worth $54,000. 29.13% of the stock is owned by institutional investors and hedge funds.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.